跳至主要内容
临床试验/NCT07619443
NCT07619443进行中(未招募)1 期

A Clinical Drug-Drug Interaction Study to Evaluate the Mutual Pharmacokinetic Effects of MK-7262 and Enlicitide in Healthy Participants

Merck Sharp & Dohme LLC2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年7月1日最近更新:
干预措施

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30
试验地点
2

研究概览

简要总结

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
19 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • The main inclusion criteria include but are not limited to the following:
  • Is in good health before randomization
  • Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

排除标准

  • The main exclusion criteria include but are not limited to the following:
  • Has a history or presence of clinically significant medical or psychiatric condition or disease
  • Has a history of cancer

研究组 & 干预措施

MK-7262 plus Enlicitide

Experimental

Participants will receive MK-7262 and enlicitide orally.

干预措施: Enlicitide (Drug)

MK-7262

Experimental

Participants will receive MK-7262 orally.

干预措施: MK-7262 (Drug)

MK-7262 plus Enlicitide

Experimental

Participants will receive MK-7262 and enlicitide orally.

干预措施: MK-7262 (Drug)

Enlicitide

Experimental

Participants will receive enlicitide orally.

干预措施: Enlicitide (Drug)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

相关资讯